Markets:

Overview

News

Currencies

International

Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

7.911 -0.069 (-0.86%)

Streaming Delayed Price Updated: 2:17 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

November 12, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable. ↗

November 12, 2024

For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering.

Via Chartmill

Vericel Stock Sees RS Rating Shoot Higher ↗

November 11, 2024

The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.

Via Investor's Business Daily

Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation

November 09, 2024

From Kirby McInerney LLP

Via Business Wire

(ADMA) - Analyzing ADMA Biologics's Short Interest ↗

October 22, 2024

Via Benzinga

Key Takeaways From ADMA Biologics Analyst Ratings ↗

October 14, 2024

Via Benzinga

This Is What Whales Are Betting On ADMA Biologics ↗

October 10, 2024

Via Benzinga

ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update

November 07, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)

November 05, 2024

From Kirby McInerney LLP

Via Business Wire

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm

November 05, 2024

From The Schall Law Firm

Via Business Wire

IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns ↗

October 10, 2024

The company reiterated its outlook for 2024 and 2025.

Via Investor's Business Daily

Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗

October 08, 2024

Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.

Via Chartmill

Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. ↗

September 24, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.

Via Chartmill

Buckle Up And Use Volitility To Your Advantage ↗

November 03, 2024

The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary.

Via Talk Markets

What You Missed On Wall Street This Past Friday ↗

November 03, 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday ↗

November 01, 2024

Via Benzinga

In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics ↗

September 20, 2024

Via Benzinga

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle ↗

November 01, 2024

The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.

Via Investor's Business Daily

ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024

October 29, 2024

Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm

October 29, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm

October 28, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm

October 21, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

October 15, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade ↗

October 15, 2024

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

Via Investor's Business Daily

Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits ↗

October 14, 2024

Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.

Via Investor's Business Daily

CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter ↗

October 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 10, 2024

Via Benzinga

ADMA Biologics Set to Join S&P SmallCap 600 Index

September 17, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference

September 10, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

What's Going On With ADMA Biologics Stock Monday? ↗

September 09, 2024

ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.

Via Benzinga

Topics Stocks

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.